CD47 and lymphoma: Noteworthy work of Weissman and collaborators in immunodeficient mice has proved preclinical efficacy of anti-CD47 mAbs in a wide range of xenograft models including leukemia (Chao et al., 2011a), lymphoma (Chao et al., 2011b), multiple myeloma (Kim et al., 2012), and several solid tumors (Edris et al., 2012; Willingham et al., 2012a).